Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × brostallicin × Clear all
NCT01091454 2018-05-08

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
48 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00060203 2014-01-16

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1/2 Completed
3 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡